Researchers at Long Island lab discover breakthrough that slows pancreatic cancer progression
Pancreatic cancer is predicted to become the second-deadliest cancer in the US by 2030.
Researchers at the Cold Spring Harbor Laboratory have found a way to slow the progression of pancreatic cancer during its early stages.
The method blocks two proteins known to make the cancer become malignant.
Researchers on Long Island have discovered a breakthrough that could aid in the mission to help maintain and possibly cure one of the most deadly forms of cancer in the United States.
Dig deeper
Cold Spring Harbor Laboratory (CSHL) has found a way to prevent the progression of cancer cells by blocking two proteins known as FGFR2 and EGFR.
Claudia Tonelli, a research investigator at CSHL, spent countless hours studying early versions of pancreatic cancer in mice and lab grown versions of human pancreatic tissue.
What they're saying
"These two proteins, together, can make the cells become malignant," Tonelli told FOX 5 New York.
Local perspective
Bill Reindl, 68, was diagnosed with stage 4 pancreatic cancer last summer.
Reindl will have to undergo chemotherapy for the rest of his life to treat the disease.
What they're saying
"Like probably most people I was in denial for a little while - this couldn't be possible," Reindl told FOX 5.
But news of CSHL's breakthrough gives both Reindl and his family hope.
"It's a golden ticket, a second chance," Amy Pollaci, Reindl's daughter, said.
Researchers at CSHL predict pancreatic cancer will become the second-deadliest cancer in America by 2030.
Pancreatic cancer is often not found and diagnosed until it is in its later stages, according to the American Cancer Association.
"The pancreas is deep inside the body, so early tumors can't be seen or felt by health care providers during routine physical exams. People usually have no symptoms until the cancer has become very large or has already spread to other organs," the ACA website states.
The Source
Information for this article was taken from local reporting by FOX 5 New York's Jodi Goldberg and interviews with the Cold Spring Harbor Laboratory.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
5 days ago
- Business Wire
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
ACCRA, Ghana--(BUSINESS WIRE)--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial announcement in April 2025, the collaboration has made remarkable progress in improving the patient journey—from early diagnosis to molecular testing and now, access to life-saving treatment. Putting patients first: RevnaBio & AstraZeneca deliver EGFR-targeted therapy to Ghana, setting a new standard in cancer care. In a landmark development, AstraZeneca launched one of their targeted therapies for EGFR mutated Lung Cancer patients in Ghana. This milestone marks a pivotal moment in the partnership's mission to bring cutting-edge, targeted therapies to patients in the sub-Saharan African region. 'This collaboration exemplifies how a synergized biomedical ecosystem such as RevnaBio's can help address long-standing institutional voids that have limited access to advanced molecular diagnostics and targeted therapies in this region,' said Dr. Derrick Edem Akpalu, Co-Founder & CEO of Revna Biosciences. 'By integrating advanced diagnostics, data, and treatment pathways, we are enabling a new standard of care for patients who have historically been underserved.' Transforming Cancer Care Through Strategic Execution Revna and AstraZeneca have rapidly translated a shared vision into tangible outcomes across diagnostics, data, and treatment infrastructure: Oncology Treatment Capacity Building: Convened a strategic Lung Cancer Symposium and Training Workshop to strengthen diagnostic capacity by equipping pathologists and oncology leaders with advanced tools and protocols for precision lung cancer diagnostics. Clinical Workflow Optimization: Operationalized EGFR biomarker testing within diagnostic workflows at leading cancer centers, advancing precision oncology and enabling targeted therapy selection at the point of care. Enabling Patient Access: Built a scalable infrastructure that connects cutting-edge molecular diagnostics to personalized treatment pathways, accelerating time-to therapy. Future-Ready Platform: Established real-time data integration to enhance clinical decision-making while building a scalable foundational framework for regional research into molecular profiling, treatment response, and resistance mechanisms. 'We are proud to see this partnership with Revna Biosciences already delivering meaningful impact for patients in Ghana,' said Dr. Khomotso Mashilane, the Medical Director African Cluster at Astrazeneca. 'By combining advanced diagnostics with access to targeted anti-cancer therapies, we are helping to ensure that patients receive the right treatment at the right time. This is a testament to the power of science and collaboration in transforming cancer care.' Voices from the Frontline 'As a triple board-certified physician, I've seen firsthand how delayed diagnosis and limited access to targeted therapies can impact outcomes,' said Dr. Preetivi Ellis, Co-Founder and Medical Head of Revna Biosciences. 'This partnership is a game-changer. We are not only treating today's patients more effectively—we are also building the genomic and real-world data infrastructure that will shape the future of cancer care.' A Shared Ethos: Today's Patients, Tomorrow's Promise This collaboration is deeply aligned with RevnaBio's ethos: caring for today's patients while gleaning genomic and real-world insights that pave the way for better diagnostics and therapies for tomorrow. By embedding precision medicine into the heart of Ghana's healthcare system, RevnaBio and AstraZeneca are setting a new standard for cancer care for the region. About AstraZeneca AstraZeneca is a global, science-led, patient-focused pharmaceutical company dedicated to transforming the future of healthcare by unlocking the power of what science can do. The company delivers life-changing medicines across oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases. About Revna Biosciences Revna Biosciences is a dual ISO-accredited precision medicine company advancing genomic research through Africa's unparalleled genetic diversity. The company's synergized ecosystem leverages its multidisciplinary laboratory facility to seamlessly integrate advanced molecular diagnostics, biobanking, and clinical and translational research services as a foundation for precision medicine advancement. With a biobank comprising samples across infectious diseases, cardiovascular diseases, oncology, rare diseases, and more, Revna supports translational science, biomarker discovery, population genetics, pharmacogenomic studies, and clinical trial optimization. Its digital platform, ROBIN, integrates real-world evidence, phenotypic data, and cross-border logistics to streamline early-phase to late-phase R&D, diagnostics validation, and population-specific therapy development for global health innovation.
Yahoo
6 days ago
- Yahoo
BATMAN brings TCR therapy out of the shadows
COLD SPRING HARBOR, N.Y., July 28, 2025 /PRNewswire/ -- Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks. Similarities between cancerous and healthy cells can affect the body's immune response, causing T cells to attack unintended targets. TCR therapy needs laser focus to prevent friendly fire. New and curiously named AI developed at Cold Spring Harbor Laboratory (CSHL) could provide just that. How does it work, and why do we need AI for the job? In biology, cells announce their state by displaying peptides on their surface. These peptides are used by T cells to distinguish cancerous and healthy cells. However, the number of peptides and TCRs in the human body is enormous, making it nearly impossible and extremely expensive to determine which peptides a given TCR can bind. To address this issue, CSHL Assistant Professor Hannah Meyer teamed with Associate Professor Saket Navlakha and postdoc Amitava Banerjee. The team developed a massive new database containing over 22,000 TCR-peptide interactions. They call it BATCAVE. Spelunking a dataset this deep would take lifetimes. So, the team built an AI model. What do you call AI engineered to comb the BATCAVE? What else but BATMAN. Navlakha explains: "We trained [BATMAN] on a bunch of TCRs and what they recognize. But give me a new TCR that is not in my database, and I need to figure out what it binds to. So, we ask, which are the best peptides I should select to make predictions?" During testing, BATMAN outperformed competing models in accurately predicting which peptides bind to a given TCR. The heroic AI also revealed why seemingly unrelated peptides get caught in the crossfire. "It's not enough to just count differences between potential targets," Meyer explains. "It matters where the difference is and what type of difference it is. Our model is already good enough to tell us if there are peptides we should be concerned about for targeted [cancer] therapies." Despite the promise, there's more to be done before BATMAN can venture from the BATCAVE for potential clinical use. As large as the database is, it houses a fraction of all possible TCR-peptide pairs. More data could enhance BATMAN's performance and help scientists answer fundamental questions about the immune system. "There's a lot of variation in the body's T-cell response," Banerjee says. "If we can accurately predict how these cells and peptides interact, that will be very helpful for designing future therapies not only for cancer, but all human illnesses." About Cold Spring Harbor LaboratoryFounded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,000 people including 600 scientists, students and technicians. For more information, visit View original content to download multimedia: SOURCE Cold Spring Harbor Laboratory Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
6 days ago
- Medscape
Hydroxychloroquine Use May Be Beneficial in Lupus Nephritis
TOPLINE: Hydroxychloroquine exposure in patients with lupus nephritis was associated with a substantially lower risk for estimated glomerular filtration rate (eGFR) decline of ≥ 30%, particularly among those with chronic kidney disease (CKD) stage ≥ 3. METHODOLOGY: Researchers conducted a retrospective study involving 209 patients with biopsy-proven incident lupus nephritis (mean age at diagnosis, 38 years; 75% women) between 1994 and 2019 identified at a single center in Wisconsin to examine the effect of hydroxychloroquine on kidney function. Hydroxychloroquine exposure status (median dose, > 5 vs ≤ 5 mg/kg/d) was determined at each visit using electronic health records, with positive exposure ascertained by an active prescription for at least 3 months at each follow-up. The primary outcome was eGFR decline of ≥ 30% at a minimum of two follow-up visits compared with baseline eGFR, or the requirement of sustained renal replacement therapy, with a mean follow-up duration of 5.4 years. The secondary outcome included an eGFR decline of ≥ 40%, and the annual eGFR slope to assess kidney function decline over time. TAKEAWAY: Time-varying exposure to hydroxychloroquine was associated with a 59% lower risk for an eGFR decline of ≥ 30% (adjusted hazard ratio [aHR], 0.41; P = .007). Similarly, hydroxychloroquine exposure was associated with a 66% lower risk for an eGFR decline of ≥ 40% (aHR, 0.34; P = .004). In patients with CKD stage ≥ 3 at lupus nephritis diagnosis, hydroxychloroquine exposure was associated with a 77% lower risk for an eGFR decline of ≥ 30% (aHR, 0.23; P = .03). Exposure to hydroxychloroquine led to significant annual reductions in eGFR slope declines of 5.12 mL/min/1.73 m2 within 5 years of a lupus nephritis diagnosis and 3.17 mL/min/1.73 m2 within 10 years. IN PRACTICE: 'These findings emphasize the importance of starting early and continuing HCQ [hydroxychloroquine] therapy to preserve kidney health alongside overall disease control even if SLE [systemic lupus erythematosus] is limited to the kidneys [lupus nephritis],' the authors of the study wrote. SOURCE: This study was led by Shivani Garg, MD, PhD, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin. It was published online on July 20, 2025, in Arthritis Care & Research. LIMITATIONS: The single academic institution setting potentially affected population representation. Data on hydroxychloroquine blood levels were unavailable to assess adherence and absorption variability. Decline of eGFR may have been missed in patients lost to follow-up or those who died at outside institutions. DISCLOSURES: This study received support from the University of Wisconsin-Madison, Institute for Clinical and Translational Research and the Clinical and Translational Science Award program from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences. One author reported receiving funding through the NIH and honoraria for presentation at a conference. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
